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Results from landmark diabetes studies have established A1C as the gold standard for assessing
long-term glycemic control. However, A1C does not provide “real-time” information about
individual hyperglycemic or hypoglycemic excursions. Real-time information provided by self-
monitoring of blood glucose (SMBG) represents an important adjunct to A1C, because it can
differentiate fasting, preprandial, and postprandial hyperglycemia; detect glycemic excursions;
identify hypoglycemia; and provide immediate feedback about the effect of food choices, phys-
icalactivity,andmedicationonglycemiccontrol.TheimportanceofSMBGiswidelyappreciated
andrecommendedasacorecomponentofmanagementinpatientswithtype1orinsulin-treated
type 2 diabetes, as well as in diabetic pregnancy, for both women with pregestational type 1 and
gestational diabetes. Nevertheless, SMBG in management of non–insulin-treated type 2 diabetic
patients continues to be debated. Results from clinical trials are inconclusive, and reviews fail to
reach an agreement, mainly because of methodological problems. Carefully designed large-scale
studies on diverse patient populations with type 2 diabetes with the follow-up period to inves-
tigate long-term effects of SMBG in patients with type 2 diabetes should be carried out to clarify
how to make the best use of SMBG, in which patients, and under what conditions.
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O
verthelast2decades,itwasﬁrmly
established that tight glycemic
control is associated with a signif-
icant reduction in serious long-term
diabetes-related complications. The
Diabetes Control and Complications
Trial demonstrated that treatment that
maintains blood glucose levels near
normal in type 1 diabetes delays the on-
set and reduces the progression of mi-
crovascular complications (1). In the
U.K. Prospective Diabetes Study, each
1% reduction in A1C was associated
with a 37% decrease in relative risk for
microvascular complications and a 21%
decreaseinrelativeriskofanyendpoint
or death related to diabetes (2).
Assessing glycemia in the manage-
ment of diabetes has always been a chal-
lenge. The urine glucose testing provided
a noninvasive inexpensive proof of severe
hyperglycemia; nevertheless, the method
was seriously limited by being only semi-
quantitative, retrospective, and signiﬁ-
cantly dependent on the patient’s
individual threshold, detecting only con-
centrations above this threshold. In the
1970s and 1980s, self-monitoring of
blood glucose (SMBG) and A1C testing
became available. In the 1990s, the con-
tinuous measurement of glucose in sub-
cutaneous tissue was introduced.
Glycosylated hemoglobin remains
the gold standard marker for assessing
long-term glycemic control. What still re-
mains elusive is to which extent the retro-
spectivereﬂectionoftheaverageglycemia
ofthepast100–120days,asexpressedby
A1C, reﬂects, even within the normal
range, a secure nondeleterious effect of
hyperglycemic excursions or hypoglyce-
micnadironorgantargets.However,A1C
does not provide “real-time” information
about individual hyperglycemic or hypo-
glycemic excursions.
To the contrary, SMBG reveals the
immediate hour-to-hour blood glucose,
which in people without diabetes, varies
only 50% throughout the day but may
vary up to10-fold in patients with diabe-
tes. Real-time information provided by
SMBG represents an important adjunct to
A1C, because it can track fasting and
postprandialhyperglycemia,detectglyce-
mic excursions and hypoglycemia, and
ultimately provides on-the-spot informa-
tion about the instant effects of food
choice, physical activity, and medication
on glycemic control. In fact, SMBG can
aid in diabetes control by doing the fol-
lowing: facilitating the development of an
individualized blood glucose proﬁle,
which can then guide doctors in treat-
ment planning for an individualized dia-
betic regimen; offering patients with
diabetes the ability to make appropriate
day-to-day treatment choices in diet and
physical activity as well as in insulin or
oral hypoglycemic agents; and improving
patient recognition of hypoglycemia. If
theprincipleofdata-drivenfeedbackgov-
erns the treatment adaptation, SMBG
couldultimatelyshoweffectivenessinsig-
niﬁcantly lowering A1C.
In pursuit of achieving near-
euglycemia while avoiding hypoglyce-
mia, the importance of SMBG is widely
appreciated and recommended as a rou-
tine part of management in patients with
type 1 or insulin-treated type 2 diabetes,
as well as in diabetic pregnancy, for both
women with pregestational type 1 and
gestational diabetes (3). In patients with
type 1 diabetes in the Diabetes Control
and Complications Trial, it was clearly
shown that SMBG in the context of mul-
tifactorial interventions is linearly corre-
lated with reductions in A1C (1). Most
authorities recommend subjects with
type 1 diabetes using multiple insulin in-
jections or insulin pump therapy to per-
form more than three capillary glucose
determinations per day, but ideally four
to six (3).
In patients with type 2 diabetes man-
agedwithnoninsulintherapiesormedical
nutritiontherapy,despitethelackofclear
evidence linking SMBG to improved gly-
cemic control, the adoption of this prac-
tice is quite common and constantly
increasing. National guidelines unani-
mously recommend SMBG in insulin-
treated type 2 diabetes; however, there is
a lack of consensus on the value of SMBG
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(NIT-DM) patients. Considering the in-
creasing incidence of type 2 diabetes and
the tremendous economic burden of the
disease both in direct and indirect costs,
but also the not neglectable cost of the
suppliesforperformingSMBG,suchagap
of a straightforward recommendation re-
garding SMBG applicability and the opti-
mal frequency of measurements is at least
query worthy.
This work focuses on the evidence
fromclinicaltrialsregardingtheimpactof
SMBG on the metabolic control and on
diabetes-related morbidity and mortality
forNIT-DMsubjects.Attentionisgivento
the question if there is evidence from the
performed studies that SMBG produces a
differential effect in a subpopulation of
type 2 diabetic subjects, on the frequency
and timing of SMBG. It reviews the cur-
rentrecommendationsforuseofSMBGin
NIT-DM patients. Also reviewed are the
available data about the cost and the cost-
effectiveness of this practice. A general
discussion of controversies is following.
EVIDENCE FOR THE
OVERALL IMPACT OF
SMBG ON METABOLIC
CONTROL— The results from nu-
merous studies aimed to answer whether
SMBG positively affects non–insulin-
treated patient care are conﬂicting. And
there is even opposite interpretation of
these trials in copious reviews or meta-
analysis attempting to evaluate the avail-
abledatafortheclinicalutilityofSMBGin
this subset of patients.
A number of randomized controlled
trials (RCTs) (4–8), reviews, and meta-
analysis (9–11) of such trials reported no
beneﬁt of SMBG on A1C values for
NIT-DM patients. More speciﬁcally, in an
early meta-analysis carried out by Coster
et al. (9), blood or urine monitoring was
notfoundtohaveanysigniﬁcanteffecton
A1C. A following review including rela-
tive studies published until 1996 failed to
locate signiﬁcant evidence of beneﬁt in
type 2 diabetes, but the authors recog-
nized the need for more studies (10). In a
recent meta-analysis analyzing nine
RCTs, Towﬁgh et al. (11) concluded that
SMBG produces a statistically signiﬁcant
but clinically modest effect in controlling
blood glucose levels in patients not
treated with insulin.
Nonetheless, other studies show ben-
eﬁt to SMBG for patients with type 2 dia-
betes using non-insulin therapies. Several
nonrandomized reports of SMBG, in the
late 1970s, were positive for SMBG (12–
14). More than a few RCTs found beneﬁ-
cial results for A1C in favor of SMBG at
the end of the study between the groups
in NIT-DM patients (15–20), and at least
twoofthemreportedasigniﬁcanteffectof
SMBG on A1C (18,19).
Sarol et al. (21) summarized eight
RCTs of 1,307 patients and found a sig-
niﬁcant reduction in A1C of 0.4%
among patients who performed SMBG.
Welschen et al. (22) scrutinizing the liter-
ature reached the conclusion that SMBG
might be effective in improving glycemic
control in patients with type 2 diabetes
who are not using insulin. In a meta-
analysis of 13 RCTs of SMBG versus no
SMBG versus self-monitoring of urine
glucose and SMBG with regular feedback
versusmonitoringwithoutfeedback,pos-
itive results on the effectiveness of inter-
ventions with SMBG in type 2 diabetes
were found (23). In an elegant systematic
review of the literature, which included
cross-sectional, longitudinal, and RCTs
from 1990 to 2006, of non–insulin-
treated patients, the impact of SMBG on
A1C levels from the cross-sectional and
longitudinal studies was inconclusive,
whereas the evidence from RCTs sug-
gested that SMBG may lead to improve-
ments in glucose control. In this search, it
is noted that few studies examined poten-
tial mediators or moderators of SMBG on
A1C levels (24).
Is there evidence from the performed
studies that SMBG would produce a dif-
ferential effect in a subpopulation of type
2 diabetic subjects? No statistically signif-
icant difference in A1C was reached after
1 year in a three-arm parallel group ran-
domized trial between the two groups of
SMBGwithpatientempowerment(group
of SMBG with advice for patients to con-
tact their doctor for interpretation of re-
sults and group with SMBG with
additional training of patients in interpre-
tation and application of the results) ver-
sus the control group in NIT-DM patients
with baseline A1C values 7.5% (25).
In an effort to avoid selection bias in-
troduced in previously performed studies
in which patients with a previous diagno-
sis of type 2 diabetes who could have
found SMBG helpful and beneﬁcial were
excluded, the Efﬁcacy of Self-Monitoring
of Blood Glucose in Patients With Newly
Diagnosed Type 2 Diabetes (ESMON)
study group recruited newly diagnosed
patients who had not previously per-
formed SMBG. No signiﬁcant differences
were noted between the self-monitoring
group versus no monitoring groups at 12
monthsinA1C,whereastheSMBGgroup
presented with a 6% higher score on the
depression subscale of the well-being
questionnaire (26).
Nowadays, the paradigm for type 2
diabetes management has been shifting
and insulin is no longer reserved as the
last resort, but is increasingly combined
with oral antidiabetic drugs at an earlier
stageofthephysicalhistoryofthedisease.
FewpreviousRCTstargetedtoanswerthe
question if SMBG is lowering A1C in this
situation, although adjustment of basal
bedtime insulin dosage is based on SMBG
readings (27,28).
EVIDENCE FOR THE IMPACT
OF SMBG ON DIABETES-
RELATED MORBIDITY AND
MORTALITY— In a German epide-
miological cohort study, which involved
3,268 patients with type 2 diabetes fol-
lowed for a mean follow-up of 6.5 years,
investigating the relationship of SMBG
with disease-related morbidity and mor-
tality, the total rate of fatal and nonfatal
events was lower in SMBG patients than
in non-SMBG patients (29).
However, conﬂicting results came
from the Fremantle Diabetes Study, in
which SMBG was not found to be inde-
pendently associated with improved sur-
vival, but the authors concluded that
inconsistent ﬁndings relating to the asso-
ciation of SMBG with cardiac death and
retinopathy may be due to confounding
incomplete covariate adjustment or
chance (30).
FREQUENCY AND TIMING
OF SMBG AMONG NIT-DM
SUBJECTS— The frequency of
SMBG, especially for NIT-DM patients,
differsfromcountrytocountry,patientto
patient, and apparently depends largely
on the intensity of treatment and meta-
bolic status, whereas cost and reimburse-
ment issues apparently inﬂuence its use.
Data gathered between 1988 and
1994 from the Third National Health and
Nutrition Examination Survey (NHANES
III) showed that 65% of the patients
treated with oral antidiabetic agents and
80% treated with diet alone had either
never monitored or monitored less than
once per month their blood glucose,
whereas SMBG at least once per day was
practiced by only 5–6% of those treated
with oral agents or diet alone. The fre-
quency of SMBG was not found to be re-
lated to glycemic control in this cross-
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often and under which circumstances pa-
tients perform SMBG in real-life condi-
tions in France comes from a national
survey of people being treated for diabe-
tes. It was found that 38% of the 2,689
people participating in the survey with
NIT-DM perform SMBG testing regularly
(six times a week on average), whereas in
only 3% of subjects, the regular use of
SMBG is not related to any special needs
or events (such as insulin treatment, oc-
currence of severe hypoglycemia, or
chronic complications) (32).
The frequency of SMBG is not consis-
tent even among the various studies look-
ing to see if there is a correlation of SMBG
and metabolic control. Among the RCTs
previously discussed to show beneﬁt to
A1CforSMBGusers,thefrequencyvaried
between ﬁve and seven capillary assays a
week. Data assessed from over 3,000
clinic visits of 228 patients with type 2
diabetesinaperiodof3yearsshowedthat
regularly monitoring and consistently
discussing blood glucose appeared to be
positively associated with better glycemic
control (33). In a large observational
study of 24,312 patients with pharmaco-
logically treated type 2 diabetes who per-
formedatleastdailyself-monitoring,A1C
levels were signiﬁcantly lower than those
who monitored less frequently (34). Ad-
versely, in a multicenter analysis includ-
ing 24,500 patients from 191 centers in
Germany and Austria, no beneﬁt of more
frequent (e.g., two measurements per
day) SMBG on metabolic control was
found in patients with type 2 diabetes on
oral antidiabetic agents or diet alone (35).
Similarly, in a recently published study,
no statistically signiﬁcant difference on
A1C was found among the one versus the
four SMBG levels per week in NIT-DM
patients, who were close to metabolic tar-
get (36).
Therearenodeﬁnitiveclinicalstudies
to answer which is the optimal frequency
of SMBG for non–insulin-treated type 2
diabetic patients; still, substantial dispar-
ityexistsamongtherecommendationson
thefrequencyandtimingofSMBGamong
international diabetes associations.
A group of experts from the U.K.
reached a consensus opinion suggesting
patients using oral antidiabetic drugs to
monitor their blood glucose at least once
daily, varying the time of testing between
fasting, preprandial, and postprandial
levels during the day (37). A global con-
sensus conference on SMBG differenti-
ated its recommendations based on the
treatment and the metabolic status of the
patients; accordingly, it was recom-
mended that patients on intensiﬁed insu-
lin therapy or insulin pump have more
than three to four readings per day. The
panel recommended that patients on oral
antidiabetic agents or daily insulin who
are above glycemic target perform SMBG
more than twice per day and those at tar-
get perform SMBG more than once per
dayandcollectpre-andpostmealglucose
test results over the week. The panel rec-
ommendedthatindividualswithdiabetes
treated with a combination of oral antidi-
abetic agents plus insulin perform more
frequent proﬁles of pre- and postprandial
glucose per week and suggested that pa-
tients with type 2 diabetes not receiving
pharmacological therapy perform more
than one proﬁle per week (38). In the
most recent clinical practice recommen-
dations, the American Diabetes Associa-
tion recognizes SMBG as an important
element in adjusting or adding new inter-
ventions and, in particular, in titrating in-
sulin doses. But it is stated that for
patients on hypoglycemic regimens that
do not include sulfonylureas or glinides
(these patients are therefore not likely to
suffer hypoglycemia), SMBG usually is
not required. However, it is stated that
SMBG may be used to determine whether
therapeutic blood glucose targets are be-
ing achieved and to adjust treatment reg-
imens without requiring the patient to
have laboratory-based blood glucose test-
ing. No speciﬁc recommendations with
respect to frequency are provided (39).
COST-EFFECTIVENESS OF
SMBG FOR NIT-DM
PATIENTS— In an era of scarce re-
sources for health care, diabetes is associ-
ated with a substantial economic burden,
andithasbeenestimatedthatpeoplewith
diabeteshavemedicalexpendituresabout
2.4 times higher than expenditures that
would be incurred by the same group in
the absence of diabetes. The total cost of
diagnosed diabetes in the U.S. in 2007
was estimated to be $174 billion (40). An
estimated conservative cost of SMBG in
the U.S. is $0.5 billion/year (41). On the
other hand, the competition among the
suppliers to develop more and more con-
venient and/or sophisticated devices is
the best indication for a multi-billion dol-
lar blossoming market. In this environ-
ment, the question if SMBG in NIT-DM
patients is cost-effective is no less than
necessary.
An incremental cost utility analysis
using the data from the Diabetes Glycae-
mic Education and Monitoring (DiGEM)
trial reached the conclusion that SMBG
with or without additional training in in-
corporating the results into self-care was
associated with higher costs (42).
Responding to Davidson’s counter-
point article (43) that claimed that SMBG
in NIT-DM subjects is a waste of money,
Neeser et al. (41) performed a cost-
effectiveness analysis of SMBG using a
Markov-state model of diabetes to assess
theclinicalimpactandrelatedcostswhen
SMBG is provided to patients not on in-
sulin therapy. They assumed a modest
improvement in A1C of 0.39%. The re-
sults of the analysis showed a slight in-
creaseinlifeexpectancy(0.083years)and
a reduced cost of complications, 70% of
which was attributable to reductions in
microvascular events. The cost per life-
year gained was approximately $39,650,
which is considered to be an acceptable
cost-effective intervention from a health
insurance perspective.
Using data from a Kaiser Permanente
“real-world” study, cost-effectiveness of
SMBG one and three times per day was
modeled. For both SMBG frequencies,
relative risks (versus no SMBG) were
lower for most complications. Although
not cost-saving, both SMBG frequencies
showed good value. Incremental cost-
effectiveness ratios were less than $8,000
perquality-adjustedlife-yeargained(44).
LIMITATIONS OF PRESENT
EVIDENCE AND FUTURE
PERSPECTIVES— The data for the
clinical utility of SMBG in NIT-DM pa-
tients are still conﬂicting, and the evi-
dence fails to be conclusive.
Alotofmethodologicalfaultsofstud-
ies performed so far are hampering the
effort to reach a conclusion of the impor-
tant question of, which is exactly the role
of SMBG in patients with type 2 diabetes
who are not receiving insulin, as has been
already identiﬁed by others (11,22,24). A
coherent question is if SMBG should be
assigned either as an ‘‘intervention,’’ or
simply as a ‘‘tool for intervention.’’ The
deﬁnition of intervention is the act of in-
tervening,interfering,orintercedingwith
the intent of modifying the outcome,
which in medicine is usually undertaken
to help treat or cure a condition. In the
studies performed so far, there is not a
common or even an adequate deﬁnition
for what exactly ‘‘SMBG intervention’’ re-
fers to. Glucometers are just tools; and
despite their value as tools to record and
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ability to capture, or the behaviors that
cause, ﬂuctuations in blood glucose lev-
els,ortomodifyactivities.Instead,SMBG
should be incorporated in the feedback
process with meaningful responses to be
necessary to generate a feedback effect,
and ultimately to change A1C levels.
There is sound evidence that co-
intervention with education on diet and
lifestyle could result in better control
(23,45). For future trials, appropriate ac-
tion based on the readings of SMBG
should be clearly deﬁned for both inter-
players of the feedback, the patient, and
the health provider, and clear guidelines
should be provided to modify food selec-
tion and physical activity level.
Vigorous attention should be paid in
the future to the fact that previously con-
ducted RCTs and systemic reviews of
RCTs failed to give a clear answer at the
interrogation as to whether SMBG is or is
not inﬂuencing metabolic control in NIT-
DM.Undoubtedly,awell-conductedRCT
istheidealstudydesignfordetermininga
causal relation between a health care in-
tervention and its putative outcomes, and
systemicreviewsofRCTsprovidethebest
evidence, graded level 1, on the effects of
preventive, therapeutic, or other inter-
ventions in medicine. Then why can’t the
selected RCTs and reviews reach a con-
clusion about the utility of SMBG in this
settingofpatients?Weshouldbecautious
when interpreting the results, and a dis-
tinction between failure to demonstrate
underlying effectiveness and good evi-
denceofineffectivenessismandatory.Im-
portantly, negative ﬁndings warrant
vigilant reading to distinguish if the re-
search failed to ﬁnd an effect where one
exists because of evaluation failure, or be-
cause there is no effect (program failure).
Inthecaseofprogramfailure,itshouldbe
clariﬁed if the failure is attributable to an
inherent inadequacy in the intervention
or is attributable to poor implementation.
Furthermore,properinterpretationofthe
evidence depends on the availability of
descriptive information on the interven-
tion and its context, so that the transfer-
ability of the evidence can be determined.
Study design per se is not an adequate
marker of evidence quality in public
health intervention evaluation (46).
As already reported by others
(11,22,24), most of the RCTs mentioned
in this work were insufﬁciently powered,
with subsequent lack of conﬁdence for
concludingthataninterventionisineffec-
tive. Besides, heterogeneity of the studies
was another limiting factor. It is quite im-
portant at the study design stage that the
characteristics of the target population
and the degree of outcome heterogeneity
be speciﬁed. It is quite expected, for ex-
ample, that patients with A1C close to
normal not show great change with
SMBG. Similarly, in type 2 diabetic pa-
tientswithverypoormetaboliccontrolon
maximal dose and number of agents, ini-
tiationofinsulinmaybetheonlysolution
to improve glycemic control and SMBG
(47).
Outcome measures should possibly
be expanded in future research. Several
recent studies have shown the respective
roleoffasting,preprandial,andpostpran-
dial glucose levels in overall diurnal hy-
perglycemia in type 2 diabetes and their
respective contribution to the mean A1C
level depending on how well blood glu-
cose levels are controlled (48). Even at
equivalent A1C levels, patients receiving
intensive therapy (involving more fre-
quent preprandial insulin injections) had
a reduction in the risk of progression of
retinopathy over time compared with pa-
tients receiving conventional treatment
(1). There is substantial evidence sup-
portingthatpostprandialglucoselevelsin
diabetesprovidebetterinformationabout
future cardiovascular risk—a fact that is
emphasized in the European Society of
Cardiology (ESC)/ European Association
for the Study of Diabetes (EASD) guide-
lines (49). In this context, it is reasonable
to speculate that a subpopulation of pa-
tients with type 2 diabetes close to the
metabolic target might beneﬁt if we were
tointervene(e.g.,withshort-actingsecre-
tagogues—not available at the time of
previous studies) to correct postprandial
glucose levels.
Apart from glycemic control, quality
oflife,well-being,andpatientsatisfaction
are issues poorly covered in previous
studies. A survey came up with the con-
clusion that SMBG in NIT-DM patients
wasassociatedwithhigherA1Clevelsand
higher psychological burden (50). Never-
theless, SMBG coupled with structured
counseling in NIT-DM patients resulted
in statistically signiﬁcant differences in
glycemic control, provided patients with
atoolfortakingonmoreself-control,and
resulted in an improved outlook on life
(51).
SMBG seems to be a logical tool for
the management of a large proportion of
type 2 diabetic patients, but it requires to
be proposed in structured counseling ed-
ucational programs adapted to the psy-
chological proﬁle and social status of the
patients. These programs must be evalu-
ated by randomized controlled trials.
There is a need for carefully designed
high-qualitylarge-scalestudiesondiverse
patient populations with type 2 diabetes
with the follow-up period to investigate
long-term effects of SMBG in patients
with type 2 diabetes, to come up with an-
swers on how to make the best use of
SMBG,inwhichpatients,andunderwhat
conditions.
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